Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remodulin in Liver Transplant
NCT01884038Phase 3Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- Jun 2008
- Primary completion
- Jun 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of treprostinil in primary graft dysfunction (PGD), reperfusion injury (IRI), sponsored by United Therapeutics Corporation. Planned start Jun 2008; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
primary graft dysfunction (PGD)reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT01884038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01884038.